We’ve recently updated our valuation analysis.

Medivir Valuation

Is MVIR B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MVIR B?

Other financial metrics that can be useful for relative valuation.

MVIR B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue25.3x
Enterprise Value/EBITDA-4.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MVIR B's PS Ratio compare to its peers?

The above table shows the PS ratio for MVIR B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average41.7x
EXPRS2 ExpreS2ion Biotech Holding
54.2x45.0%kr487.4m
ATORX Alligator Bioscience
18.2x107.8%kr389.9m
NICA Nanologica
57.5x122.9%kr276.6m
ACOU AcouSort
36.8xn/akr259.0m
MVIR B Medivir
33.5x28.7%kr522.1m

Price-To-Sales vs Peers: MVIR B is good value based on its Price-To-Sales Ratio (33.5x) compared to the peer average (41.7x).


Price to Earnings Ratio vs Industry

How does MVIR B's PE Ratio compare vs other companies in the SE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a44.4%
n/an/an/a

Price-To-Sales vs Industry: MVIR B is expensive based on its Price-To-Sales Ratio (33.5x) compared to the Swedish Biotechs industry average (17.7x)


Price to Sales Ratio vs Fair Ratio

What is MVIR B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MVIR B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio33.5x
Fair PS Ratio0.06x

Price-To-Sales vs Fair Ratio: MVIR B is expensive based on its Price-To-Sales Ratio (33.5x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).


Share Price vs Fair Value

What is the Fair Price of MVIR B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MVIR B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MVIR B's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MVIR B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentkr9.37
kr24.57
+162.2%
59.0%kr50.00kr11.00n/a5
Nov ’23kr7.97
kr24.57
+208.3%
59.0%kr50.00kr11.00n/a5
Oct ’23kr7.69
kr24.57
+219.5%
59.0%kr50.00kr11.00n/a5
Sep ’23kr7.74
kr24.57
+217.4%
59.0%kr50.00kr11.00n/a5
Aug ’23kr8.21
kr20.42
+148.7%
40.2%kr30.60kr11.00n/a5
Jul ’23kr7.81
kr20.42
+161.5%
40.2%kr30.60kr11.00n/a5
Jun ’23kr7.91
kr17.88
+126.0%
40.4%kr30.00kr11.00n/a4
May ’23kr7.82
kr17.88
+128.6%
40.4%kr30.00kr11.00n/a4
Apr ’23kr8.06
kr17.88
+121.8%
40.4%kr30.00kr11.00n/a4
Mar ’23kr7.95
kr18.83
+136.9%
43.0%kr30.00kr11.00n/a3
Feb ’23kr8.56
kr18.83
+120.0%
43.0%kr30.00kr11.00n/a3
Jan ’23kr11.20
kr18.83
+68.2%
43.0%kr30.00kr11.00n/a3
Dec ’22kr10.56
kr20.50
+94.1%
46.3%kr30.00kr11.00kr9.052
Nov ’22kr9.49
kr26.00
+174.0%
15.4%kr30.00kr22.00kr7.972
Oct ’22kr10.02
kr26.00
+159.5%
15.4%kr30.00kr22.00kr7.692
Sep ’22kr10.82
kr26.00
+140.3%
15.4%kr30.00kr22.00kr7.742
Aug ’22kr9.90
kr26.00
+162.6%
15.4%kr30.00kr22.00kr8.212
Jul ’22kr8.17
kr26.00
+218.2%
15.4%kr30.00kr22.00kr7.812
Jun ’22kr8.33
kr26.00
+212.1%
15.4%kr30.00kr22.00kr7.912
May ’22kr7.92
kr26.00
+228.3%
15.4%kr30.00kr22.00kr7.822
Apr ’22kr8.22
kr26.00
+216.3%
15.4%kr30.00kr22.00kr8.062
Mar ’22kr8.81
kr26.00
+195.1%
15.4%kr30.00kr22.00kr7.952
Feb ’22kr7.99
kr26.00
+225.4%
15.4%kr30.00kr22.00kr8.562
Jan ’22kr8.30
kr26.00
+213.3%
15.4%kr30.00kr22.00kr11.202
Dec ’21kr11.80
kr26.00
+120.3%
15.4%kr30.00kr22.00kr10.562

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies